Inicio › Leucemia mielógena aguda › California › Sacramento
Ensayos clínicos de Leucemia mielógena aguda en Sacramento, CA
12 estudios para Leucemia mielógena aguda buscan participantes en centros de Sacramento y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
ReclutandoFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Mercy Cancer Center - Sacramento, Sacramento
- Woodland Memorial Hospital, Woodland · A 16 mi de distancia
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ReclutandoFase 1
- UC Davis, Sacramento
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
ReclutandoFase 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Sutter Medical Center, Sacramento
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
ReclutandoFase 2
- University of California Davis Health (UC Davis Health), Sacramento
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
ReclutandoFase 1/2
- University of California, Davis, Sacramento
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
ReclutandoFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
Otros estudios en Sacramento
- Cáncer de pulmón de células no pequeñas29 estudios
- Cáncer de pulmón22 estudios
- Cáncer de seno20 estudios
- Cáncer de próstata19 estudios
- Cáncer metastásico16 estudios
- Fallo cardíaco12 estudios
- Cáncer de páncreas12 estudios
- Cáncer (todos los tipos)11 estudios
- Cáncer de colon11 estudios
- Cáncer de vejiga10 estudios
- Cáncer del colon y del recto10 estudios
- Diabetes tipo 29 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.